Background: Epigenetic alterations such as DNA methylation are known as the main cause of different types of cancers through inactivation of tumor suppressor genes, especially thyroid cancer. Identification of novel and effective markers are important in diagnosis and prevention of thyroid cancer. In the present study, the expression and methylation of Solute carrier family 5 member 8 () in Papillary Thyroid Carcinoma (PTC) in comparison to multinodular goiter (MNG) have been studied.
Methods: Overall, 41 patients with PTC and 36 patients affected by MNG were recruited from four hospitals in Tehran and Qazvin, Iran in 2018. Thyroid tissues were obtained during thyroidectomy. RNA and DNA were extracted from thyroid tissues. Quantitative RT-PCR assay was performed for determining the mRNA level of while Methylation-Sensitive High-Resolution Methylation was applied for assessing the methylation status.
Results: Methylation status of three regions composed of 52 CpG islands in the promoter of gene was studied by HRM assay. level in PTC tissues was significantly downregulated in average 0.4 fold in comparison with MNG tissues (=0.05). The aberrant methylation of (b) region was remarkably different in PTC and MNG cases. The promoter methylation of (c) was significantly related to mutations and vascular invasion in PTC patients.
Conclusion: The aberrant promoter hyper methylation of SLC5A8 was related to aggressive PTC. Therefore, there is some evidence to support the hypothesis that could be a paly important role in the development of PTC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276613 | PMC |
| http://dx.doi.org/10.18502/ijph.v51i3.8940 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing surgical outcomes in papillary thyroid carcinoma with Hashimoto's Thyroiditis: a retrospective comparative study of unilateral and total thyroidectomy.
Sci Rep
December 2024
Department of Thyroid Surgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410013, Hunan, P. R. China.
The management of papillary thyroid carcinoma (PTC) concurrent with Hashimoto's thyroiditis (HT) lacks standardized guidelines, especially concerning surgical strategies. This study aimed to compare unilateral thyroidectomy (UT) with total thyroidectomy (TT) in PTC-HT patients to optimize clinical management and improve postoperative outcomes. This retrospective study included PTC-HT patients undergoing thyroid surgery at a tertiary academic medical institution from January 2018 to August 2023.
View Article and Find Full Text PDFGenotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.
Front Endocrinol (Lausanne)
December 2024
Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Fukushima, Japan.
Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disorder, accompanied by multiple endocrine neoplasms of the parathyroid, pancreas, pituitary, and other neoplasms in the adrenal glands. However, in some cases, patients clinically diagnosed with MEN1 may be genotype-negative.
Case Presentation: A 56-year-old female was diagnosed with MEN1 based on a macroprolactinoma (19 mm in diameter), primary hyperparathyroidism, and a cortisol-producing adrenal adenoma, without a family history.
CT-based radiomics features for the differential diagnosis of nodular goiter and papillary thyroid carcinoma: an analysis employing propensity score matching.
Front Oncol
December 2024
Medical Imaging Center, The first Affiliated Hospital of Jinan University, Guangzhou, China.
Purpose: This study aims to evaluate the effectiveness of CT-based radiomics features in discriminating between nodular goiter (NG) and papillary thyroid carcinoma (PTC).
Methods: A retrospective cohort comprising 228 patients with nodular goiter (NG) and 227 patients with papillary thyroid carcinoma (PTC) diagnosed between January 2018 and December 2022 was consecutively enrolled. Propensity score matching (PSM) was applied to align patients with NG and PTC.
YTHDF3-induced degradation of P4HA2 mRNA inhibits glycolysis in papillary thyroid cancer through Hippo signaling pathway.
Int J Biol Macromol
December 2024
Thyroid Surgery Department, Xiangya Hospital, Central South University, Changsha 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China. Electronic address:
Background: Prolyl-4-hydroxylase-A2 (P4HA2) is a pivotal enzyme involved in the regulation of tumorigenesis and progression. However, the precise biological roles and potential functions of P4HA2 in papillary thyroid cancer (PTC) remain poorly elucidated.
Methods: Gain-of-function and loss-of-function approaches were employed to investigate the underlying biological effects of P4HA2 on PTC cell proliferation and metastasis both in vitro and in vivo.
Does a Restrictive Diagnostic Work-up for Thyroid Nodules Lead to a Different Papillary Thyroid Cancer Patient Population? A Comparison Between Dutch and U.S. T1-T3 Patient Population.
World J Surg
December 2024
Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Introduction: The 2015 American Thyroid Association guidelines recommend de-escalating surgical treatment for papillary thyroid cancer (PTC). We hypothesize that the Dutch PTC population might differ due to a restrictive diagnostic policy that mainly selects symptomatic and palpable thyroid nodules for further diagnostics, potentially selecting relatively more aggressive tumors. We aimed to describe the Dutch PTC population because differences in populations can have consequences for the adoption of foreign guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!